Tissue Repair Limited Pursues ASX Delisting Citing Low Liquidity and High Listing Costs

Low Share Liquidity Drives Delisting Decision

Tissue Repair Limited identified severely limited share trading liquidity as a key factor prompting its delisting application. During the 90 days preceding the announcement, the company’s average daily trading value was approximately $6,000, which the board describes as indicative of a virtually inactive market for its shares. Such low volumes cause pricing distortions where small trades disproportionately impact share price, undermining the reliability of market valuations as true reflections of the company’s intrinsic value and strategic position.

The board further highlights that the shareholder base consists of a concentrated group of long-term investors alongside numerous smaller retail shareholders holding unmarketable parcels. This ownership structure has reduced the free float available for trading and rendered the ASX listing ineffective as a liquidity provider. The combination of concentrated ownership and a significant retail shareholder segment with small, illiquid holdings has led the board to conclude that the listing offers limited practical benefit to most shareholders while imposing substantial administrative and financial burdens on the company.

High Annual Listing Costs Strengthen Economic Case for Delisting

Tissue Repair Limited incurs significant annual costs to maintain its ASX listing, estimated by the board at approximately $800,000. These costs include ASX listing fees, compliance obligations, legal expenses, and administrative overheads associated with operating as a public company. The board views these expenses as disproportionate relative to the company’s current size, development stage, and the limited benefits derived from the listing given the low trading activity and price discovery.

Beyond direct financial costs, the board notes a substantial opportunity cost in management time and resources dedicated to meeting ASX regulatory requirements. This compliance effort diverts senior management focus away from operational execution and long-term value creation. By transitioning to unlisted status, the company aims to reallocate both capital and management attention toward core business activities without the ongoing administrative and regulatory burdens of public company status.

Concentrated Shareholding Limits Opposition to Delisting

The company’s share register features a concentrated ownership base, with a core group of long-term shareholders holding a significant portion of issued capital. This concentration reduces the free float available for public trading, limiting the ASX listing’s effectiveness as a liquidity and price discovery mechanism. Additionally, these long-term shareholders are less likely to oppose delisting, as they typically hold shares for strategic or long-term value reasons rather than short-term trading.

Alongside this core group, many smaller shareholders hold unmarketable parcels—positions too small to trade economically under standard broker minimums. While these investors represent a notable portion of shareholder numbers, they own only a small fraction of issued capital. This mismatch means the ASX listing provides limited tangible benefit to these shareholders but imposes listing costs borne collectively by the company and all shareholders, creating economic inefficiency that delisting would remove.

Board Highlights Market Capitalisation Disconnect from True Asset Value

The board asserts that the company’s current market capitalisation does not accurately reflect the underlying value of its net assets and strategic positioning. This disconnect stems from low trading volumes, illiquid market price discovery failures, and short-term market sentiment dominating sporadic share price movements. By moving to unlisted status, the board believes the company can refocus stakeholders and management on fundamental value creation rather than unreliable short-term market pricing.

The board emphasizes that operating as an unlisted public company will grant greater strategic flexibility to execute its business plan and pursue long-term value maximisation without the distractions and pressures of public market expectations. The company also notes that delisting is a tactical repositioning, not a permanent exit from public markets, leaving open the possibility of relisting if conditions improve.

ASX Grants Conditional In-Principle Approval for Delisting

ASX has indicated likely approval of Tissue Repair Limited’s delisting request, contingent on the company meeting specified conditions. The primary requirement is shareholder approval through a special resolution at a general meeting, ensuring broad shareholder consent. Additionally, the delisting cannot occur earlier than one month after shareholder approval, providing a cooling-off period for shareholders to sell shares on-market if desired.

Other ASX conditions include comprehensive disclosure in the meeting notice and explanatory statement, detailing delisting timing, shareholder sale options before delisting, and post-delisting share disposal procedures. The company must also comply with ASX Guidance Note 33, apply for share suspension at least two business days prior to delisting, and publicly release ASX’s decision terms. Tissue Repair Limited has committed to full compliance with these requirements.

Shareholder Vote to Decide Delisting Outcome

Tissue Repair Limited will hold a general meeting where shareholders will vote on the delisting proposal by special resolution, requiring a supermajority for approval. The company will send a notice of meeting to all shareholders, including an explanatory statement outlining the board’s rationale, delisting consequences, and share registry transition details. Shareholders may vote in person or by proxy. The vote outcome will determine whether the company proceeds with delisting or remains listed.

Post-Delisting Share Trading to Shift to Off-Market Transactions

If approved, Tissue Repair Limited shares will cease ASX quotation, and shareholders will lose the ability to trade on the exchange. CHESS holdings will automatically convert to issuer-sponsored sub-register holdings without shareholder action, ensuring continuity of ownership records. Post-delisting, share transfers will occur exclusively through private off-market transactions, a more complex and less liquid process than exchange trading. Shareholders should consider this reduced liquidity when voting.

Company Background and Strategic Outlook

Tissue Repair Limited is an Australian biotechnology and life sciences company headquartered in Chatswood, NSW. Its move to unlisted status reflects challenges faced by small-cap biotech firms in aligning lengthy R&D timelines and capital needs with short-term market expectations and trading dynamics. The company believes its assets, intellectual property, and development programs hold greater value than current market pricing indicates.

The delisting strategy aims to eliminate public company compliance costs, enabling the company to focus capital and management on advancing tissue repair and regenerative medicine initiatives. The company stresses that delisting is not a permanent departure from public markets and retains the option to relist if commercial milestones or market conditions improve.

Delisting Process Timeline and Next Steps

The delisting will proceed according to ASX conditions and regulatory timelines. Following this announcement, a notice of meeting with the general meeting date will be sent to shareholders. After the special resolution vote, a mandatory one-month period will allow shareholders to trade shares on ASX before suspension. The company must apply for share suspension at least two business days before delisting. Once delisted, shares will trade only off-market. The final delisting date will be communicated after shareholder approval.